You can buy or sell ZIOP and other stocks, options, ETFs, and crypto commission-free!
ZIOPHARM Oncology Inc Common Stock, also called Ziopharm Oncology, is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. Read More The company was founded on September 9, 2003 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Seeking AlphaMar 5
ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2018 Results - Earnings Call Transcript
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Q4 2018 Earnings Conference Call March 5, 2019 4:30 PM ET Company Participants David Connolly - IR Laurence Cooper - CEO David Mauney - President Conference Call Participants Reni Benjamin - Raymond James Eric Joseph - J.P. Morgan Sean Lee - H. C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Ziopharm Fourth Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answe...
Yahoo FinanceMar 5
Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Phase 1 Trial of Sleeping Beauty-TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 – - Eden BioCell to advance third-generation Sleeping Beauty CAR-T for Greater China – - Third cohort enrolling patients in Controlled IL-12 combination trial with OPDIVO® for recurrent glioblastoma (rGBM) – - Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo® f...
Stock Price, News, & Analysis for ZIOPHARM Oncology
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic...
Expected May 9, After Hours